top of page
NxGen_banner-01.png

Smart port.

Early detection.

Better outcomes.

THE NEXT GENERATION IN REMOTE PATIENT MONITORING

Advances in Personalized Medicine and Digital Health technologies are revolutionizing modern medicine. NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.

port image shutterstock_1093980773.jpg

WHAT IS
NXGEN PORT?

bullet-01.png
bullet-01.png
bullet-01.png
bullet-01.png
bullet-01.png

Port efficacy + new sensor technology
 

Remotely measure real-time physiological distress
 

Digital health platform coordinating patients + providers
 

Early intervention
 

Patient management

waves_bg-01.png

THE 
PROBLEM

COSTS $2.3 BILLION ANNUALLY

50%

Of patients on chemo with a port suffer from neutropenia which puts them at greater risk for infection and complications

20%

Of patients have complications ranging from minor to major, most frequently infections and thrombosis, leading to port removal, hospitalization, higher medical costs and treatment

25%

Of women on trastuzumab for HER2+ breast cancer suffer cardiotoxicity and cardiac function decline

50%

Of patients have to delay or cancel treatment due to poor blood counts on treatment days

Problem

THE 
SOLUTION

solution-01.png
arrows-01.png

1

REMOTE MONITORING

Physiologic changes and trends measured in vivo.

solution-02.png
arrows-02.png

2

DATA + ANALYTICS

Real-time information about a patient's health status.

solution-03.png

3

REPORT TO PROVIDER

Relevant measures and actionable data.

telehealth-visits-man-tablet-920x520.jpeg

4

TAKE ACTION

Virtual patient management.

Solution

How does NXgenPort work?

THE 
VALUE

NXgen Port PROVIDES EARLY 
INDICATION OF:
  • Infection

  • Changes in heart function

  • Blood cells counts

  • Oxygen levels

  • Body temperature

  • Proteins (i.e., hemoglobin)

  • Cancer prevalence

  • Device leakage or failure

value-01.png

PHYSICIANS

  • Early indication of infection
     

  • Remote patient monitoring
     

  • Put “eyes and hands” on patients
     

  • Actionable data
     

  • Maximize clinic time

value-02.png

PATIENTS

  • Baseline of health before treatment begins
     

  • Awareness of acceptable symptoms
     

  • Alert to infection Peace of mind
     

  • Limits “micro-traumas”

value-03.png

INSURANCE

PAYERS

  • Reduce unexpected hospitalizations
     

  • Manage costs due to adverse events

value-04.png

PROVIDERS

  • Reduce treatment cancelations or delays
     

  • Longitudinal data
     

  • Manage costs Increase efficiency

value-05.png

PHARMA

  • Virtual clinical trial support

  • Passive data collection
     

  • Adherence and drug efficacy

Value
Team

TEAM

Headshot_close.jpg

Cathy Skinner, MA

Co-founder/Co-inventor

Chief Executive Officer

  • Entrepreneur with 12 years of startup experience (Thrivors.com and TheArtofWell.com).
     

  • Nationally recognized Cancer Exercise Specialist with the American College of Sports Medicine.
     

  • 12 years of working face-to-face with cancer patients and survivors providing wellness programs.
     

  • Invited panelist and guest speaker, Cancer Survivorship Conferences, Employer Benefits, Pharma Patient Advocacy conferences.
     

  • Former Chair of the Minnesota Cancer Alliance.
     

  • Board member with one non-profit organization.

Rosanne_Welcher_2022_edited.jpg

Rosanne Welcher, PhD, MBA, RAC 

Co-founder/Co-inventor

Chief Operating Officer

  • Award-winning R&D and Business Leader with cross-functional expertise in Medical Devices/IVD business development, product development, regulatory and clinical affairs, quality assurance, manufacturing and commercialization.
     

  • Over 25 years in med devices/IVD with people management experience.
     

  • Former CSO Agilent Technologies, Companion Diagnostics.
     

  • Invited guest speaker, Personalized Medicine, Regulatory/Clinical and IVD conferences.
     

  • 17 issued patents.
     

  • Board Director with two non-profit organizations.

Kelly Headshot.jpg

Kelly Christian, MS

R&D and Engineering

  • 30 years bringing new medical devices to market.

  • 20 years developing new chemo ports including developing the first PowerPort (TM).

  • Former Senior Director at Becton Dickinson as a biomedical engineer, team leader, and program director.

  • Launched products with an annual value of almost a billion dollars and improved outcomes for millions of patients worldwide.

  • 30 issued patents related to ports.

  • Industrial Advisory Board Member for the school of Biomedical Engineering for the University of Utah.

Advisors

ADVISORS

Tufia Haddad, MD

Oncology, Product Advisor and
Patient/Physician Perspectives

John Slump

Board Chair, Investor Relations and Finance

Rich Nazarian, BS, MS

Engineering, Business Strategy and Partnerships

Serge Alexanian, MD

Medical Advisor

Surgical and Hospital Liaison

Formerly of

Nancy Lelicoff, MS

Engineering, Regulatory, Quality and Research

Formerly of

Lisa Suennen

Digital Health Strategy and Investor Relations

Alan Feinerman, PhD

Research and Device Design

Vincent Kuenen, BS, MS

Engineering, Software Development and Patient Advocate

Contact

CONTACT US

Tel: +1 651-587-5440

Saint Paul, MN USA

To submit a product or investor inquiry, please type your information here. We look forward to connecting with you.

Thanks for submitting!

bottom of page